New data on tofacitinib for polymyalgia rheumatica (PMR) induction and tapering therapy was published on 2022-01-01. The publication details results from a trial evaluating tofacitinib alongside glucocorticoid therapy in patients with active PMR, as described in an internal summary of the event.
Background
Tofacitinib is being investigated for its potential role in managing polymyalgia rheumatica, specifically as an induction and tapering therapy alongside glucocorticoids. Polymyalgia rheumatica is an inflammatory condition characterized by muscle pain and stiffness, predominantly affecting older adults, and is often treated with corticosteroids.
What this means
The publication of these data provides insights into the use of tofacitinib as an induction and tapering therapy for polymyalgia rheumatica. While specific efficacy and safety metrics are not provided in the available information, the publication signifies progress in understanding potential treatment strategies for patients with active PMR receiving glucocorticoid therapy. Clinicians and researchers can review the full publication for detailed findings on the use of tofacitinib in this patient population.
Source
The information regarding this publication event for tofacitinib is based on an internal summary titled 'ITTGPMR — Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica', dated 2022-01-01. The event was recorded with PubMed as the source label.